ValuentumAd

Official PayPal Seal
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Latest Valuentum Commentary

Nov 21, 2017
Roche’s Hemlibra Looks Very Promising
Image shown: Roche's shares caught some relief recently. We're big fans of clinical data reads. Thus far in 2017, we've posted updates on Roche, Shire Plc and Bioverativ--each with extensive aspirations in the field of hemophilia. In light of recent developments, a follow-up only seems appropriate as Roche’s Hemlibra is poised to disrupt the marketplace.
Aug 21, 2017
Shire Plc Continues To Underwhelm
Image Shown: Shire's equity has been under enormous pressure as of late. The share price of Shire Plc remains under pressure after posting decent quarterly results in early August. On the surface, the results themselves do not merit the equity hitting a new low, in our view. However, the market continues to grapple with the future direction of the company. Let’s examine the various components of Shire’s underlying business in this article.
May 5, 2017
Dividend Increases/Decreases for the Week Ending May 5
Let's take a look at companies raising/lowering their dividends this week.
May 4, 2017
Valuentum’s 3 Breakthroughs in the Field of Finance and More
Valuentum's President Brian Nelson pauses for a picture before speaking at the CFA Society of Houston in March 2017. Let’s cover Valuentum’s 3 major breakthroughs in the field of finance. The first one is big and may challenge you to rethink everything you think you know about investing.
Apr 4, 2017
Can Vertex Pharmaceuticals Dominate the Race to Treat Cystic Fibrosis?
Cystic Fibrosis is a rare disease that afflicts an estimated seventy-five thousand patients worldwide. Vertex Pharmaceuticals is the first to market with a combination treatment to treat a portion of the overall patient population. Will Vertex win the race to bring forth a triple therapy to treat the vast majority of those afflicted?
Feb 15, 2017
These Medical Instruments Won’t Heal Your Portfolio
The medical instruments industry is a group characterized in part by diversity, and as such, there are ideas of all shapes and sizes. Let’s dig into two overvalued companies in the space and what put them in their current positions.
Jan 19, 2017
Fair Value Estimate Changes: Facebook, Twitter, Caterpillar and More...
Let's have a look at the reasons behind several of the recent fair value changes we've made on companies across our coverage universe as of late.
Nov 16, 2016
Pharma, Biotech and How to Consider Investing In It
The Valuentum analyst team digs deep into recent trends in big pharma and biotech from the lofty pricing of drugs to political and competitive pressures to ETF considerations and beyond. ~10 mins.
May 9, 2016
Dividend Increases/Decreases for the Week Ending May 6
Let's take a look at companies raising/lowering their dividends this week.
Mar 20, 2015
Hooray! Biogen’s Breakthrough Alzheimer’s Drug?
Biogen’s potential new drug could help millions of people suffering from Alzheimer’s.


Latest News and Media
The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.